Research Opportunities for C-type Natriuretic Peptide

BioMarin Pharmaceutical Inc. is a world leader in developing and commercialising first- or best-in-class therapies for rare genetic diseases. C-type natriuretic peptide (CNP) is a growth factor with receptors expressed in many cells and systems throughout the body (e.g., cardiovascular, pulmonary, central nervous system (CNS), musculoskeletal and reproductive tissues). BioMarin Pharmaceutical Inc. is seeking early research ideas and preclinical proposals for CNP-related research projects.

Approaches of Interest

- Preclinical research applications that have an opportunity to address a serious unmet medical need. Applications in genetic diseases of the musculoskeletal system, cardiovascular system, and CNS, as well as haematological diseases, are of the highest interest.
- CNP and its receptor transmembrane guanylyl cyclase receptor (NPRB) are expressed ubiquitously throughout many mammalian cells and tissues. Targeted cells/tissues should express NPRB.
- Evidence of MAP kinase pathway involvement or cGMP deficiency in disease pathogenesis.
- Diseases where guanylyl cyclase agonists or MEK, phosphodiesterase and FGFR inhibitors have been tested.

Out of Scope

- Certain research applications, including but not limited to aspects of cancer, growth deficiency, short stature, and approaches that require modifications to CNP may be excluded from this campaign.

Developmental Stages of Interest

- Opportunities at basic research phase to research phases prior to Phase I clinical trial are within scope.
- Opportunities with in vitro (cell models), in vivo (animal models) or ex vivo experiments will be considered.

Submission Information

- Submission of either this optional submission form or alternatively one page, 200-300 words briefs are encouraged, along with any optional supplementary information (e.g., relevant publications, patents, slide decks).
- In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

BioMarin Pharmaceutical Inc. is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis.

Opportunities sought

- Technologies
- Academics and expertise
- Centres of excellence
- Research projects
- Spinout companies

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: 3rd May 2022 - 10:59 pm GMT

Have any questions? Contact our team at discover@in-part.co.uk

BioMarin Pharmaceutical Inc. take pride in going where the science leads them, pioneering breakthrough treatments for debilitating and life-threatening conditions where they can significantly improve upon the current standard of care.

© 2022 IN-PART All rights reserved